Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | MATK | P42679 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14539667 | 0.88 | SMPD3 (0.41) | ABL1KDRHRH4CHEK1CCNA2 | |
| SCHEMBL11930847 | 0.88 | ABL1 (0.38) | ABL1KDRHRH4HRH3CHEK1 | |
| SCHEMBL11930846 | 0.88 | ABL1 (0.38) | ABL1KDRHRH4HRH3CHEK1 | |
| SCHEMBL11930848 | 0.85 | HRH4 (0.38) | AKT1ABL1KDRHRH4HRH3 | |
| SCHEMBL11930843 | 0.85 | HRH4 (0.38) | AKT1ABL1KDRHRH4HRH3 | |
| SCHEMBL11931211 | 0.85 | HRH4 (0.41) | AKT1ABL1KDRHRH4HRH3 | |
| SCHEMBL14539517 | 0.82 | KDR (0.38) | ABL1KDRCHEK1CCNA2CDK2 | |
| SCHEMBL11931212 | 0.81 | CDK2 (0.44) | ABL1KDRHRH4CHEK1CCNA2 | |
| SCHEMBL15393810 | 0.81 | AKT1 (0.39) | AKT1HRH4HRH3CHEK1CCNA2 | |
| SCHEMBL15393817 | 0.81 | AKT1 (0.39) | AKT1HRH4HRH3CHEK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1931676-B1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORP (US) | 2011-11-16 | — | — | EP | disclosed |
| US-7776865-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776865-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| WO-2007041712-A1 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | AKT1 236/4885ABL1 88/4885KDR 2086/4885 |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CHEK1, CHEK2, BUB1 | AKT1 470/4885ABL1 122/4885KDR 1715/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | AKT1 236/4885ABL1 88/4885KDR 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.